<DOC>
	<DOCNO>NCT00322036</DOCNO>
	<brief_summary>This multinational , randomize , double blind , placebo control , parallel group study compare safety efficacy daily dose 800 mg twice daily MPC-7869 placebo . Study subject diagnosis mild dementia Alzheimer 's type . Subjects may take approved medication Alzheimer 's disease provide dose stable least 6 month .</brief_summary>
	<brief_title>Global Efficacy Study MPC-7869 Treat Patients With Alzheimer 's</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Flurbiprofen</mesh_term>
	<criteria>1 . Have diagnosis probable Alzheimer 's disease 2 . Men woman age great equal 55 year live community time enrollment ( ie , live rest home nursing care facility ) . 3 . Signed subject Informed Consent Form ( ICF ) willing able participate duration study . 4 . Ability read understand English , Dutch , Danish , Flemish , French , German , Italian , Spanish Swedish ensure compliance cognitive testing study visit procedure . 5 . At least 6 year education , sufficient work history exclude mental retardation . 6 . Female subject must surgically sterile postmenopausal &gt; 1 year . 7 . Adequate vision hear participate study assessment . 8 . Subjects must reliable caregiver read , understand speak language . 1 . Current evidence cause dementia.. . 2 . History , evidence , active malignancy , except basal cell carcinoma squamous cell carcinoma skin , within 24 month prior entry . Men prostate cancer may enrol discretion sponsor . 3 . Use investigational therapy within 30 day , 5 halflives , whichever longer , and/or use AD immunotherapy prior screen . 4 . Major surgery relate complication resolve within 12 week prior Day 1 . 5 . Previous participation MPC7869 clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Alzheimer Disease</keyword>
	<keyword>Dementia</keyword>
</DOC>